- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.11.25 | Ensoma halves workforce after transitioning genetic medicine to the clinic | ||
| 20.11.25 | Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach | ||
| 20.11.25 | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| 19.11.25 | Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO | ||
| 19.11.25 | Celltrion still thinking bigger than biosimilars with option for $350M antibody deal | ||
| 19.11.25 | Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir | ||
| 19.11.25 | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| 19.11.25 | GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space | ||
| 18.11.25 | How Biogen is returning to its roots with a West Coast immunology outpost | ||
| 18.11.25 | Vanda tackles Wegovy-driven vomiting, sparking race to phase 3 | ||
| 18.11.25 | Jefferies' London conference cements reputation as 'JP Morgan for Europe' | ||
| 18.11.25 | Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial | ||
| 17.11.25 | Genmab sheds another clinical ADC from $1.8B ProfoundBio buy | ||
| 17.11.25 | Repare finds fix as biotech agrees to XenoTherapeutics buyout | ||
| 17.11.25 | Bayer opens Beijing incubator and names initial occupants, tightening ties to China | ||
| 17.11.25 | J&J buys into Halda cell death tech with $3B acquisition, beefing up prostate cancer pipeline | ||
| 17.11.25 | Nxera lays off 15% of staff, pivots pipeline focus in profitability push | ||
| 17.11.25 | Nuvalent shares lung cancer data, sparking race to FDA for would-be Pfizer rival | ||
| 14.11.25 | Sensei shrinks workforce by 65%, terminates 3 executive roles | ||
| 14.11.25 | Merck pays $9.2B for Cidara, picking up flu antiviral spurned by J&J | ||
| 14.11.25 | BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes | ||
| 14.11.25 | Analysts skeptical Applied Tx can get rare disease drug to market as FDA talks drag on | ||
| 13.11.25 | Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk | ||
| 13.11.25 | Third Arc Bio pens back-loaded $840M pact for Adagene's masking T-cell engager tech | ||
| 13.11.25 | Century, Candel and MacroGenics call time on certain clinical trials to conserve cash |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .